Appian To Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 MCLEAN, Va., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: APPN) today announced that it will release financial results for the fourth quarter and full year ended December 31, 2025, before the U.S. financial markets open on Thursday, February 19, 2026. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, pa...
Bassett Announces Fourth Quarter Conference Call BASSETT, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Bassett Furniture Industries, Inc. (Nasdaq: BSET) today announced it will host a conference call with management on Thursday, February 5, 2026, at 9:00 a.m. ET to discuss its fourth quarter 2025 financial results. The Company plans to issue its earnings release after the market closes on Wednesday, February 4, 2026. Rob Spilman, Chairman and CEO will host the call, along with Mike Daniel, Senior Vice President and CFO. The public is invited to listen to the conference call by webcast, accessi...
Bassett Announces Regular Quarterly Dividend BASSETT, Va., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Bassett Furniture Industries, Inc. (Nasdaq: BSET) announced today that its Board of Directors has declared a regular quarterly dividend of $0.20 per share of common stock, payable on February 27, 2026, to shareholders of record at the close of business on February 13, 2026. About Bassett Furniture Industries, Inc. Bassett Furniture Industries, Inc. (NASDAQ: BSET) is a leading provider of high-quality home furnishings with a wide range of distribution types. Bassett sells approximately 60% of its...
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports the advancement of Seres’ portfolio, including Phase 2-ready lead candidate SER-155 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq...
Two Directors at Cormedix Inc sold/sold after exercising options 74,000 shares at between 11.880USD and 12.000USD. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the co...
Appian Corporation to Present at the Barclays 23rd Annual Global Technology Conference MCLEAN, Va., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN), today announced that Serge Tanjga, Chief Financial Officer, will present at the Barclays 23rd Annual Global Technology Conference in San Francisco, CA. The fireside chat is scheduled for Wednesday, December 10, 2025 at 8:40am Pacific Time and will be webcast live at the following link: Replays of the fireside chat will be available for a limited time under the “News and Events” section of the Company’s investor relations website at ...
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET. A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at and will be available for replay following the event. About Seres Thera...
Appian Announces Third Quarter 2025 Financial Results Third quarter cloud subscriptions revenue increased 21% year-over-year to $113.6 millionThird quarter total revenue increased 21% year-over-year to $187.0 million MCLEAN, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue: Cloud subscriptions revenue was $113.6 million, up 21% compared to the third quarter of 2024. Total subscriptions revenue, which includes sales of our cloud subscriptio...
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint...
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 8471287. To join ...
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infections CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial product...
Bassett Announces Regular Quarterly Dividend BASSETT, Va., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Bassett Furniture Industries, Inc. (Nasdaq: BSET) announced today that its Board of Directors has declared a regular quarterly dividend of $0.20 per share of common stock, payable on November 28, 2025, to shareholders of record at the close of business on November 14, 2025. About Bassett Furniture Industries, Inc.Bassett Furniture Industries, Inc. (NASDAQ: BSET) is a leading provider of high-quality home furnishings with a wide range of distribution types. Bassett sells approximately 60% of its p...
Appian To Announce Third Quarter 2025 Financial Results on November 6, 2025 MCLEAN, Va., Oct. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: APPN) today announced that it will release financial results for the third quarter ended September 30, 2025 before the U.S. financial markets open on Thursday, November 6, 2025. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, participants can join the call, us...
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19–22 in Atlanta, Georgia. Presentation DetailsAbstract ID: 2106936Title: Clinical and...
Bassett Reports Fiscal Year 2025 Third Quarter Results BASSETT, Va., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Bassett Furniture Industries, Inc. (Nasdaq: BSET) reported today its results of operations for its third quarter ended August 30, 2025. Q3 Consolidated Business Highlights: [FY 25 vs. FY 24, unless otherwise specified] Revenues increased 5.9% from the prior year quarter. Excluding sales from Noa Home Inc., which closed in late 2024, consolidated revenues increased 7.3%.Operating income was $0.6 million, or 0.7% of sales as compared to a loss of $(6.4) million for the prior year quarte...
Bassett Announces Third Quarter Conference Call BASSETT, Va., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Bassett Furniture Industries, Inc. (Nasdaq: BSET) today announced it will host a conference call with management on Thursday, October 9, 2025, at 9:00 a.m. ET to discuss its third quarter 2025 financial results. The Company will issue its earnings release after the market closes on Wednesday, October 8, 2025. Rob Spilman, Chairman and CEO will host the call, along with Mike Daniel, Senior Vice President and CFO. The public is invited to listen to the conference call by webcast, accessible thr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.